Escitalopram in Anxiety Associated Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

Status:

WITHDRAWN

Escitalopram in Anxiety Associated Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

Lead Sponsor:

Hull University Teaching Hospitals NHS Trust

Conditions:

Anxiety

COPD

Eligibility:

All Genders

40-80 years

Phase:

PHASE3

Brief Summary

Anxiety and depression are common in patients with severe chronic obstructive pulmonary disease (COPD). Frequently exacerbation's of breathlessness are associated with panic/fear and indeed this may b...

Eligibility Criteria

Inclusion

Male/females aged between 40-80 years.
Previous diagnosis of COPD confirmed by the GOLD criteria.
At least two previous admissions to hospital for acute exacerbation of COPD.
Physician diagnosed anxiety
At least Mild anxiety score on HADS and GAD-7
On a stable therapeutic regimen for COPD for 8 weeks prior to inclusion
Known history of cigarette smoking at least 10 pack yrs
Willing and able to comply with study procedures
Able to provide written informed consent to participate

Exclusion

Current or past diagnosis of asthma
Long-term oxygen therapy
Currently on treatment with anti-depressives
Serious inter-current illness (eg lung cancer)
One year survival considered unlikely
Patients who have evidence of alcohol or drug abuse
Participation in another clinical trial with an investigational drug in four weeks preceding the screening visit
Clinically significant or unstable concurrent disease e.g. left ventricular failure, diabetes mellitus
Known or suspected hypersensitivity to escitalopram

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01522092

Last Update

March 29 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)